PREPAID EXPENSES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Oct. 31, 2022 |
May 25, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Feb. 26, 2021 |
|
| Insurance annual preminum | $ 349,455 | ||||
| Insurance expense | $ 221,357 | ||||
| Common stock, shares issued | 16,984,570 | 8,778,555 | |||
| Common stock value | $ 170 | $ 88 | |||
| Investor [Member] | |||||
| Common stock, shares issued | 27,500 | ||||
| Warrants | 60,000 | ||||
| Fair value of share issuance | $ 39,453 | ||||
| Per share value | $ 2.56 | ||||
| New Lease Agreement [Member] | |||||
| Monthly rent | $ 6,000 | ||||
| Common stock, shares issued | 5,333 | ||||
| Common stock value | $ 49,600 | ||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|